GPRC5D/CD3 BiTEs Clinical Trials
3 recruitingDrug
Phase 23
Showing 1–3 of 3 trials
Recruiting
Phase 2
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07106684
Recruiting
Phase 2
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07106710
Recruiting
Phase 2
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT07106736